Andrea Rivero

17.7k total citations
27 papers, 166 citations indexed

About

Andrea Rivero is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Andrea Rivero has authored 27 papers receiving a total of 166 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 12 papers in Oncology and 6 papers in Genetics. Recurrent topics in Andrea Rivero's work include Lymphoma Diagnosis and Treatment (16 papers), Viral-associated cancers and disorders (10 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Andrea Rivero is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Viral-associated cancers and disorders (10 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Andrea Rivero collaborates with scholars based in Spain, United States and Philippines. Andrea Rivero's co-authors include Armando López‐Guillermo, Pablo Mozas, Laura Magnano, Eva Giné, Elı́as Campo, Ferran Nadeu, Neus Villamor, Julio Delgado, Alfredo Rivas‐Delgado and Ángel Gil de Miguel and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Scientific Reports.

In The Last Decade

Andrea Rivero

23 papers receiving 160 citations

Peers

Andrea Rivero

PFM

ONCOL

GENET

EPIDE

IMMUN

Laure Lebras France

Simona Sammassimo Italy

Huiqiang Huang China

William Wu United States

Bernard De Prijck Belgium

Arnuparp Lekhakula Thailand

Tsuneaki Hirakawa Japan

Lauren Pommert United States

Emil Kumar United Kingdom

Alicia Bailén Spain

Laure Lebras France

Andrea Rivero

78 ×0.8

PFM

115 ×1.5

ONCOL

32 ×0.8

GENET

27 ×0.8

EPIDE

22 ×0.7

IMMUN

Citations per year, relative to Andrea Rivero Andrea Rivero (= 1×) peers Laure Lebras

Countries citing papers authored by Andrea Rivero

Since Specialization

Citations

This map shows the geographic impact of Andrea Rivero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Rivero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Rivero more than expected).

Fields of papers citing papers by Andrea Rivero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Rivero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Rivero. The network helps show where Andrea Rivero may publish in the future.

Co-authorship network of co-authors of Andrea Rivero

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Rivero. A scholar is included among the top collaborators of Andrea Rivero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Rivero. Andrea Rivero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nadeu, Ferran, Silvia Martín, Pablo Mozas, et al.. (2023). MALAT1 expression is associated with aggressive behavior in indolent B-cell neoplasms. Scientific Reports. 13(1). 16839–16839. 5 indexed citations

Rivero, Andrea, Pablo Mozas, Laura Magnano, & Armando López‐Guillermo. (2023). Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review. Frontiers in Oncology. 13. 1170394–1170394. 6 indexed citations

Ferrés, Abel, Thomaz E. Topczewski, Andrea Rivero, et al.. (2023). The ghost tumour revisited. Corticosteroids in primary central nervous system lymphoma: diagnostic, prognostic and therapeutic implications. British Journal of Neurosurgery. 39(3). 352–359.

López, Néstor, Emmanuel Coloma, Celia Cardozo, et al.. (2022). Hospital at home treatment with remdesivir for patients with COVID-19: real-life experience. International Journal of Infectious Diseases. 127. 124–128. 5 indexed citations

Magnano, Laura, Andrea Rivero, & Estella Matutes. (2022). Large Granular Lymphocytic Leukemia: Current State of Diagnosis, Pathogenesis and Treatment. Current Oncology Reports. 24(5). 633–644. 6 indexed citations

Valero, Juan García, Ferran Nadeu, Renaud Morin, et al.. (2022). Immunocompetent 3D Follicular Lymphoma Model: A Preclinical Tool to Design Tailored Immunotherapies. Blood. 140(Supplement 1). 9279–9280. 1 indexed citations

Mozas, Pablo, Andrea Rivero, & Armando López‐Guillermo. (2021). Past, present and future of prognostic scores in follicular lymphoma. Blood Reviews. 50. 100865–100865. 11 indexed citations

Mozas, Pablo, Andrea Rivero, Alfredo Rivas‐Delgado, et al.. (2021). Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma. Annals of Hematology. 100(5). 1231–1239. 5 indexed citations

Bansal, Pankaj, David Abia‐Trujillo, Andrea Rivero, et al.. (2021). V.I.T.A.M. in COVID 19: A Systematic Approach to a Global Pandemic. SHILAP Revista de lepidopterología. 15.

10.

Mozas, Pablo, Andrea Rivero, Alfredo Rivas‐Delgado, et al.. (2021). Prognostic ability of five clinical risk scores in follicular lymphoma: A single‐center evaluation. Hematological Oncology. 39(5). 639–649. 5 indexed citations

11.

Mozas, Pablo, Andrea Rivero, Alfredo Rivas‐Delgado, et al.. (2021). The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma. Leukemia & lymphoma. 63(4). 903–910. 9 indexed citations

12.

Rivero, Andrea, Pablo Mozas, Mònica López‐Guerra, et al.. (2021). Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution. Cancers. 13(15). 3900–3900. 12 indexed citations

13.

Mozas, Pablo, Marc Sorigué, Alfredo Rivas‐Delgado, et al.. (2020). The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients. European Journal Of Haematology. 106(3). 428–432. 1 indexed citations

14.

Mozas, Pablo, Ferran Nadeu, Alfredo Rivas‐Delgado, et al.. (2020). Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience. Blood Cancer Journal. 10(3). 31–31. 25 indexed citations

15.

Magnano, Laura, Alba Navarro, Mònica López‐Guerra, et al.. (2020). Chronic lymphocytic leukaemia and prolymphocytic leukaemia. Two coins or two sides of the same coin?. Haematologica. 105(9). e484–e484. 3 indexed citations

16.

Mozas, Pablo, Alfredo Rivas‐Delgado, Andrea Rivero, et al.. (2020). High serum levels of IL-2R, IL-6, and TNF-α are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era. Leukemia Research. 94. 106371–106371. 11 indexed citations

17.

Mozas, Pablo, Andrea Rivero, Alfredo Rivas‐Delgado, et al.. (2020). A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma. Leukemia & lymphoma. 62(1). 104–111. 6 indexed citations

18.

Stoddard, Gregory J., et al.. (2019). Quality Improvement Intervention for Universal Lipid Screening in Children Aged 9 to 11 Years. Clinical Pediatrics. 58(14). 1528–1533. 5 indexed citations

19.

Prieto, Ruth, et al.. (2009). Epidemiology of pneumococcal meningitis hospitalizations in pediatric population in Spain (1998–2006). Vaccine. 27(20). 2669–2673. 24 indexed citations

20.

Muynck, A. De, et al.. (1979). Estudio epidemiológico, clínico y terapéutico del Chagas agudo en Santa Cruz, Bolivia. 5. 2–16. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact